Galinpepimut-S shows a 41% reduction in risk of death in Phase 3 AML trial

SELLAS Life Sciences Group has reported positive topline results from its pivotal Phase 3 REGAL trial, in which its investigational WT1-targeted immunotherapeutic vaccine galinpepimut-S (GPS) met the primary endpoint of overall...
Your Weekly Life Sciences Digest

Your Weekly Life Sciences Digest

Get an online subscription and you can unlock any article you come across, getting instant emails when our site updates, too.

The global peptide capacity race: who is investing in GLP-1 manufacturing?

The rapid growth of the GLP-1 drug market is driving a major expansion of global peptide manufacturing capacity. Pharmaceutical companies are investing in their own production networks, while contract development and manufacturing organisations (CDMOs) are building new facilities, acquiring specialist manufacturers and upgrading existing sites. Not all announced projects are dedicated exclusively to GLP-1 medicines. Several investments concern broader peptide manufacturing platforms that may also support GLP-1-related programmes, depending on...

Eli Lilly agrees to acquire Calytrix Bio for up to $1.5 billion

Eli Lilly and Company has entered into a definitive agreement to acquire privately held biotechnology company Calytrix Bio, Inc. in a transaction valued at up to $1.5 billion in cash. The deal adds a preclinical antibody programme targeting mutant calreticulin (mCALR) to Lilly's pipeline for myeloproliferative neoplasms (MPNs), including essential thrombocythemia and myelofibrosis. Under the agreement, Calytrix shareholders may receive an upfront payment followed by additional payments linked to the...

WHO prequalification, inspections and the “WHO certificate”: understanding the differences

The World Health Organization (WHO) conducts inspections through its Inspection Services, primarily in connection with the assessment and ongoing oversight of products submitted to its Prequalification Programme. A separate mechanism, the WHO Certification Scheme, does not mean that WHO itself issues GMP certificates: the relevant documents are issued by competent national authorities using WHO-recommended formats. Scope of WHO prequalification and GMP inspections This article focuses primarily on human medicines and active...

HPRA outlines regulatory priorities for 2026–2029

Ireland’s Health Products Regulatory Authority (HPRA) has published its Strategic Plan 2026–2029, setting out four priorities for adapting regulatory oversight to scientific advances, evolving European legislation and challenges affecting the availability of health products. The strategy focuses on regulatory development, digital transformation, stakeholder cooperation and organisational capability. Published as the HPRA marks 30 years since its establishment as an independent body and National Competent Authority, the plan describes how the...

PIC/S adopts Revision 7 of its Pharmaceutical Inspection Co-operation Scheme

The Pharmaceutical Inspection Co-operation Scheme (PIC/S) has adopted Revision 7 of its foundational document, PIC/S 1/95, introducing updates to its governance, membership framework, inspector training and international regulatory cooperation. The revised Scheme was adopted by the PIC/S Committee in Istanbul, Türkiye, on 2 November 2026 and entered into force on the same date. PIC/S announced the revision on 12 November. PIC/S remains a legally non-binding cooperation framework The revised Scheme confirms...

GMP & Guidance

Documents available for download

EU–US GMP mutual recognition becomes fully operational for veterinary medicines

The European Union and the United States have completed the assessment of all EU Member States' competent authorities under the pharmaceutical Good Manufacturing Practice (GMP) Mutual Recognition Agreement (MRA)...

UAE EDE introduces new regulatory controls for peptide products and molecules

Read the official EDE Circular No. 46/2026 and download the full regulatory document in the TOP-Pharma Resource Centre. The Emirates Drug Establishment (EDE) has introduced a comprehensive regulatory framework for...

FDA updates its human drug facility inspection framework under ConOps 2.0

The US Food and Drug Administration (FDA) has updated its operating framework for evaluating and inspecting human drug manufacturing facilities. The revised Concept of Operations (ConOps), dated 21 October...

FDA proposes framework for individualized gene therapies as CMS expands access

The US Food and Drug Administration (FDA) has proposed a regulatory framework for individualized human genome editing therapies, while the Centers for Medicare & Medicaid Services (CMS) plans to...
spot_img

Professional Interpreters for
GMP Inspections

Clear Communication for Your GMP Inspection.
We provide expert on-site interpreters who understand pharmaceutical terminology to ensure smooth communication with the inspectors.